



20 June 2024

ASX ANNOUNCEMENT (ASX:CBL)

TGA Approval Granted for DROVE Autonomous Wheelchair Module

Control Bionics Limited (ASX: CBL) is pleased to announce that its autonomous wheelchair module, DROVE, has been officially included as a Class 1 Medical Device in the Australian Register of Therapeutic Goods. This significant milestone follows almost 12 months of extensive internal and external testing, ensuring the highest standards of safety and effectiveness for our innovative mobility solution.

With this inclusion, Control Bionics now has the ability to commence commercial sales of the DROVE module in Australia. We are excited to announce that the official launch of DROVE will take place in the coming weeks, marking a new era in assistive mobility technology. DROVE is a world first and an introductory video can be viewed here www.controlbionics.com/products/drove/.

DROVE is designed and manufactured in Australia, to provide powered wheelchair users with unprecedented independence and ease of use within their own homes. This advanced module integrates seamlessly with existing wheelchair systems, enabling users to navigate their environment autonomously and safely.

CEO Jeremy Steele said the following: 'This is a fantastic confirmation of the quality of our DROVE solution. I am delighted for our team who have worked for years to design, test and get this device registered. I am even more excited to be able to provide independence to Australians currently living with conditions that impact their ability to control their own wheelchair.'

Mr Steele continued: 'Work is also progressing well on a similar approval in the US with the FDA, supported by a grant from the ALS Association received earlier this year. We are encouraged by the revenue growth opportunity DROVE provides Control Bionics.'

This announcement was authorized by CBL CEO Jeremy Steele.

About Control Bionics:

Control Bionics is a medical device company dedicated to assisting patients whose ability to communicate is compromised by conditions such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless, wearable device that detects minute signals sent from the brain to any skeletal muscle, capturing EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology integrates eye gaze technology, allowing the eye gaze to move a cursor on a computer screen, while the NeuroNode acts as a mouse button. Control Bionics uniquely combines touch, eye, and NeuroNode control, offering patients the ability to express themselves with significantly faster speed and less fatigue.

We have recently expanded our offering to include mobility solutions with the launch of DROVE, an autonomous wheelchair module that allows powered wheelchair users to operate their wheelchairs independently in their own homes.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore, and Japan.

Investors and Media

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley – Company Secretary
brettcrowley@controlbionics.com

Investor Relations:

Joe Durak
Executive Director & Founder
Lynx Advisors
joe@lynxadvisors.com.au
+61 414 465 582

For further information, visit our website: www.controlbionics.com

Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia
T: +61 3 9897 3576
W: www.controlbionics.com
ABN: 45 115 465 462

For further information visit the website: <https://www.controlbionics.com/>